Work

Single Institution Experience with Myeloma Patients for Commercially Approved BCMA Chimeric Antigen Receptor T Cell Therapy (CART) Idecabtagene-Vicleucel (Ide-cel)

Year: 2022

Type: article

Source: Transplantation and Cellular Therapy

DOI: 10.1016/s2666-6367(22)00457-2

Authors: Nausheen Ahmed, Al-Ola Abdallah, Sarah Bromert, Allison Appenfeller, Haitham Abdelhakim, Rajat Bansal, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Anurag K Singh, Sunil Abhyankar, Siddhartha Ganguly, Joseph P. McGuirk, Leyla Shune

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

OpenAlex ID: W4221047643

FWCI: 0.091

Cites:

Cited by: 1

Related to: 10